What question did this study set out to answer?

To characterize structural and functional alterations in preglomerular vessels during chronic angiotensin II-induced hypertension and evaluate the protective role of the endothelin receptor antagonist bosentan.

December 1, 1997Hypertension

Bosentan Prevents Preglomerular Alterations During Angiotensin II Hypertension

View Full Paper

Ask AI

Bookmark

Why the study?

Does bosentan prevent preglomerular vascular alterations in rats with angiotensin II-induced hypertension?

Population

Rats with chronic angiotensin II (Ang II)-induced hypertension

Comparison

Bosentan 30 mg/kg/day for 10 days… vs Ang II alone and control rats

Design

Preclinical

Follow-up

10 days

Authors

DCDaniel CasellasUniversity of Alabama NBNathalie BouriquetState University of New York AHAbderraouf HériziUniversité de Montpellier

Discussion

Member takes

Implication

Endothelin antagonism may protect preglomerular vessels in experimental hypertension; leaves open translation to human renoprotection.

Key Points

To characterize structural and functional alterations in preglomerular vessels during chronic angiotensin II-induced hypertension and evaluate the protective role of the endothelin receptor antagonist bosentan.
Administered angiotensin II (400 ng/kg/min) with or without bosentan (30 mg/kg/day) to rats for 10 days, recording systolic blood pressure and albuminuria.
Isolated preglomerular vessels after hydrochloric acid maceration to evaluate vascular lesions, medial thickness, and cell proliferation across arcuate branches, interlobular arteries, and afferent arterioles.
Assessed autoregulatory responses to perfusion pressure shifts (60 to 160 mm Hg) along interlobular arteries and afferent arterioles using blood-perfused juxtamedullary nephron preparations.
Systolic blood pressure increased by 56±3 mm Hg in the angiotensin II group and by 54±6 mm Hg in the angiotensin II plus bosentan group, with albuminuria increasing similarly in both cohorts.
Angiotensin II induced vascular lesions characterized by a 74% increase in media thickness affecting 36±6% of arcuate branches, 20±5% of interlobular arteries, and 4±1% of afferent arterioles, which were strikingly reduced by bosentan.
Autoregulatory vasoconstriction responses across interlobular arteries and afferent arterioles were suppressed by angiotensin II but fully preserved by co-treatment with bosentan.

Structured PICO

Does bosentan prevent preglomerular vascular alterations in rats with angiotensin II-induced hypertension?

Population

Rats with chronic angiotensin II (Ang II)-induced hypertension

Intervention

Bosentan (mixed endothelin receptor antagonist) 30 mg/kg/day for 10 days, co-administered with Ang II

Comparator

Ang II alone (400 ng/kg/min for 10 days) and control rats

Outcome

Structurofunctional alterations of preglomerular vessels (vascular lesions, media thickness, lipid droplets) and autoregulatory responsessurrogate

In a rat model of Ang II-induced hypertension, endothelin-1 receptor antagonism with bosentan prevents preglomerular vascular structural lesions and autoregulatory impairment independently of blood pressure reduction.

Cite This Study

Casellas et al. (1997) studied this question.

synapsesocial.com/papers/6a855dd1beaf5c5b09108e56 https://doi.org/10.1161/01.hyp.30.6.1613

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Bosentan Prevents Preglomerular Alterations During Angiotensin II Hypertension

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Bosentan Prevents Preglomerular Alterations During Angiotensin II Hypertension

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider